ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
리오프로(압식시맙) 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 지리적 범위 및 시장 입지의 확대, 관련 산업 및 가치 사슬로의 확장, 종합적인 지원 서비스 및 자원의 제공 증가, 광범위한 산업에 걸친 통합의 확대, 다양한 부문의 특정 요구를 충족하기 위한 맞춤형 솔루션의 제공 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 자동화의 채택, 치료 프로토콜에 첨단 치료제의 통합, 유전체학 및 바이오마커 식별의 발전, 맞춤형 의약품, 맞춤형 치료법 등이 있습니다.
관상동맥질환(CAD)의 유병률 증가가 리오프로(압식시맙) 시장의 성장을 견인할 것으로 예측됩니다. CAD는 플라크 축적으로 인해 관상 동맥이 좁아지거나 막혀 심장으로의 혈류가 감소하고 심장 마비의 위험이 높아지는 질환입니다. CAD의 발병률 증가는 주로 식습관, 신체 활동 부족, 흡연, 비만, 당뇨병 및 고혈압의 증가와 같은 생활 습관 요인의 영향이 큽니다. 리오프로(압식시맙)는 혈소판 응집을 억제하고 합병증의 위험을 낮춤으로써 혈관 성형술과 같은 경피적 관상 동맥 중재술 (PCI)과 같은 시술 중 혈전 형성을 방지하기 위해 CAD 관리에 사용됩니다. 예를 들어, 2024년 10월 미국 질병통제예방센터(CDC)는 관상동맥 질환이 심장 질환의 주요 원인이며, 2022년 37만 1,506명의 사망 원인으로 보고되었습니다. 또한 20세 이상 성인 중 5%, 즉 20명 중 1명이 CAD를 앓고 있습니다. 그 결과, CAD의 유병률 증가가 리오프로(압식시맙) 시장의 성장을 촉진할 것으로 보입니다.
리오프로(압식시맙) 시장의 성장은 고령 인구의 증가에 의해 촉진될 것으로 예상됩니다. 고령 인구는 일반적으로 65세 이상의 개인을 의미하며, 이 연령 기준은 상황에 따라 다릅니다. 이 인구층의 증가는 주로 기대수명 연장, 의료 기술의 발전, 생활 조건의 개선 때문입니다. 리오프로(압식시맙)는 항혈소판제로, 특히 노화로 인해 심혈관 질환 위험이 높은 환자들이 경피적 관상동맥 중재술(PCI) 중 및 후에 혈전 형성을 줄여 심장 건강을 개선하고 합병증을 감소시킵니다. 예를 들어, 커뮤니티 생활 관리국(Administration for Community Living)은 2022년 인구 중 17.3%가 65세 이상이었으며, 이 비율은 2040년까지 22%로 증가할 것으로 예상됩니다. 따라서 노인 인구 증가가 리오프로(압식시맙) 시장 성장에 크게 기여할 것으로 예상됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 리오프로(압식시맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 리오프로(압식시맙) 시장 : 성장률 분석
세계의 리오프로(압식시맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 리오프로(압식시맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 리오프로(압식시맙) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 리오프로(압식시맙) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
20ml
50ml
세계의 리오프로(압식시맙) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
불안정 협심증
심혈관계
기타
세계의 리오프로(압식시맙) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
외래수술센터(ASC)
클리닉
재택 케어
병원
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 리오프로(압식시맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 리오프로(압식시맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
리오프로(압식시맙) 시장 : 경쟁 구도
리오프로(압식시맙) 시장 : 기업 프로파일
Janssen Pharmaceuticals(Johnson & Johnson)
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
리오프로(압식시맙) 시장(2029년) : 새로운 기회를 제공하는 국가
리오프로(압식시맙) 시장(2029년) : 새로운 기회를 제공하는 부문
리오프로(압식시맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
ReoPro (Abciximab) is an anticoagulant, commonly known as a "blood thinner," used in emergency treatments for heart attacks. It is a monoclonal antibody designed to target the glycoprotein IIb/IIIa receptor, helping to prevent blood clots during percutaneous coronary interventions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The ReoPro (Abciximab) market primarily includes 20ml and 50ml formulations. The 20ml variant contains 2 mg/mL of Abciximab in a buffered solution. Its applications span unstable angina, cardiovascular conditions, and others, with end-users such as ambulatory surgical centers, clinics, homecare settings, and hospitals.
The Reopro (abciximab) market research report is one of a series of new reports from The Business Research Company that provides Reopro (abciximab) market statistics, including Reopro (abciximab) industry global market size, regional shares, competitors with a Reopro (abciximab) market share, detailed Reopro (abciximab) market segments, market trends, and opportunities, and any further data you may need to thrive in the Reopro (abciximab) industry. This Reopro (abciximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The reoPro (abciximab) market size is expected to see rapid growth in the next few years. It will grow to $1,923.8 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing geographical reach and market presence, expanding into related industries and value chains, increasing in providing comprehensive support services and resources, growing integration across a broad spectrum of industries, increasingly offering tailored solutions to meet the specific needs of different sectors. Major trends in the forecast period include adoption of automation, Integration of advanced therapeutic agents into treatment protocols, advancements in genomics and biomarker identification, personalized medicine, personalized therapies.
The increasing prevalence of coronary artery disease (CAD) is expected to drive the growth of the reoPro (Abciximab) market. CAD occurs when the coronary arteries narrow or become blocked due to plaque buildup, leading to reduced blood flow to the heart and a higher risk of heart attacks. The rising incidence of CAD is mainly influenced by lifestyle factors such as poor diet, physical inactivity, smoking, obesity, and the increasing rates of diabetes and hypertension. ReoPro (Abciximab) is used in CAD management to prevent blood clots during procedures like percutaneous coronary intervention (PCI), such as angioplasty, by inhibiting platelet aggregation and lowering the risk of complications. For example, in October 2024, the Centers for Disease Control and Prevention (CDC) reported that coronary heart disease remains the leading cause of heart disease, responsible for 371,506 deaths in 2022. Additionally, 5% of adults aged 20 and older, or 1 in 20, suffer from CAD. As a result, the growing prevalence of CAD is set to propel the reoPro (Abciximab) market forward.
The growth of the reoPro (Abciximab) market is expected to be driven by the increasing geriatric population. The geriatric population typically refers to individuals aged 65 and older, with this age threshold varying by context. The rise in this demographic is mainly due to increased life expectancy, advancements in healthcare, and improved living conditions. ReoPro (Abciximab), an antiplatelet medication, helps elderly individuals by reducing the risk of blood clot formation during and after percutaneous coronary interventions (PCIs), especially in those at higher risk of cardiovascular events due to aging, thus improving heart health and reducing complications. For instance, the Administration for Community Living reported that 17.3% of the population was aged 65 or older in 2022, with this proportion projected to rise to 22% by 2040. Consequently, the growth of the geriatric population is expected to contribute significantly to the reoPro (Abciximab) market.
The increasing prevalence of cardiovascular diseases (CVDs) is another key factor driving the growth of the reoPro (Abciximab) market. CVDs encompass a wide range of heart and blood vessel disorders, including coronary artery disease, heart attacks, heart failure, stroke, and hypertension. The growing prevalence of CVDs is attributed to an aging population, unhealthy lifestyle choices, and rising rates of risk factors like obesity, diabetes, and hypertension. ReoPro (Abciximab) benefits CVD patients by inhibiting platelet aggregation, thus reducing the risk of blood clot formation during procedures such as angioplasty or stent placement and preventing further complications like heart attacks and strokes in individuals with atherosclerosis or other cardiovascular conditions. In May 2024, the CDC reported that heart disease caused 702,880 deaths in 2022, accounting for 1 in every 5 fatalities. Additionally, about 805,000 people in the U.S. suffer a heart attack each year, with 605,000 being first-time events and 200,000 occurring in individuals with a history of heart attacks. As a result, the increasing prevalence of cardiovascular diseases is expected to drive the growth of the reoPro (Abciximab) market.
Key player operating in the reopro (abciximab) market is Janssen Pharmaceuticals (Johnson & Johnson).
North America was the largest region in the reopro (abciximab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reoPro (abciximab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the reoPro (abciximab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The reoPro (abciximab) market consists of sales of biosimilars of Abciximab, cardiovascular intervention devices, ReoPro compounding kits, anticoagulants, and platelet aggregation inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
ReoPro (Abciximab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on reopro (abciximab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for reopro (abciximab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The reopro (abciximab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: 20ml; 50ml
2) By Application: Unstable Angina; Cardiovascular; Other Applications
3) By End-User: Ambulatory Surgical Centers; Clinics; Homecare Settings; Hospitals
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. ReoPro (Abciximab) Market Characteristics
3. ReoPro (Abciximab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. ReoPro (Abciximab) Market Trends And Strategies
5. ReoPro (Abciximab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global ReoPro (Abciximab) Growth Analysis And Strategic Analysis Framework
6.1. Global ReoPro (Abciximab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global ReoPro (Abciximab) Market Growth Rate Analysis
6.4. Global ReoPro (Abciximab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global ReoPro (Abciximab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global ReoPro (Abciximab) Total Addressable Market (TAM)
7. Global ReoPro (Abciximab) Market Pricing Analysis & Forecasts
8. ReoPro (Abciximab) Market Segmentation
8.1. Global ReoPro (Abciximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20ml
50ml
8.2. Global ReoPro (Abciximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Unstable Angina
Cardiovascular
Other Applications
8.3. Global ReoPro (Abciximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ambulatory Surgical Centers
Clinics
Homecare Settings
Hospitals
9. Global ReoPro (Abciximab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. ReoPro (Abciximab) Market Regional And Country Analysis
10.1. Global ReoPro (Abciximab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global ReoPro (Abciximab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
